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Abstract: Interstitial fluid, obtained by gentle centrifugation of the renal biopsy specimen, is highly enriched in elements 
directly secreted by the kidney tissue and is suitable for proteomic analysis. Here we describe the first clinical application 
of renal interstitial fluid analysis in a subset of samples obtained from patients affected by idiopathic membranous 
nephropathy. 
We included in the study fifty-one patients with different pathologic diagnoses. We identified the proteomic pattern of 
idiopathic membranous nephropathy with mass spectrometry analysis by comparing these samples with two controls: 
normal kidney and IgA nephropathy. Proteomic results were validated by immunofluorescence analysis of renal tissues 
and Western blot of serum, urines and podocyte cell cultures. 
We observed an increased expression of PDZ and LIM domain protein 5 (PDLI5) and LIM domain binding protein 3 
(LDB3) providing first evidence of the differential expression of these LIM domain-related proteins in kidney and urines 
of patients with idiopathic membranous nephropathy. 
Interstitial fluid can be considered a valuable biological fluid in the discovery phase of biomarkers. In order to validate its 
clinical use, it is pivotal to assess the availability of the biomarkers in ‘usual’ samples: blood and/or urine. PDLI5 and 
LDB3 share a common LIM domain suggesting a possible role in the cytoskeleton organization and they appear up-
regulated in glomeruli of patients affected by idiopathic membranous nephropathy. Furthermore the two proteins become 
highly abundant in the urine of patients affected by idiopathic membranous nephropathy. In conclusion, our approach may 
be considered a novel method for identifying candidate biomarkers for patients suffering from membranous nephropathy 
and other glomerulonephrites. 
Keywords: Membranous nephropathy, proteomics, podocyte, interstitial fluid, proteinuria, nephrotic syndrome. 
INTRODUCTION 
 Idiopathic membranous nephropathy (iMN) is the most 
common glomerulonephritis and the first cause of nephrotic 
syndrome in the adult population. iMN can have an indolent 
and benign course, although about 30% of patients progress 
toward end stage renal failure (ESRF) within ten years [1-4]. 
The most likely pathogenesis of iMN is autoimmune and this 
hypothesis is corroborated by the observation of thickened 
glomerular basal membrane in histological preparations, as a 
consequence of subepithelial deposits of immune complexes. 
One of the first antigens reported to be involved in the human 
iMN in a rare neonatal condition is neutral endopeptidase [5, 
6] (NEP), supporting the theory that podocytes act as a  
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source of antigens for the in situ formation of subepithelial 
immune complex deposits. Recently Beck LH et al. identified 
new candidate autoantigens involved in the classic adult 
form of iMN: M-type phospholipase A2 receptor (PLA2R), a 
glycoprotein expressed by podocytes, colocalizes with IgG 
in the subepithelial immune complex deposits [7]. A second 
research group (Prunotto M et al.) found that IgG4 from 
iMN patients reacted toward aldose reductase (AR) and 
manganese superoxide dismutase (SOD2), thus adding two 
more targets to the MN antingen list [8], which has been 
hypothesized to be further extending [9-11]. 
 Despite progress in the understanding of etiopatho- 
genesis, the diagnosis of iMN is definitively established only 
by renal biopsy, which usually shows predominant IgG 
subepithelial deposits [12, 13] and thickening of the glomerular 
basal membranes. The pathological features and the clinical 
characteristics at presentation have a poor prognostic value. 
About 30% of patients may enter a spontaneous remission; 
other patients may benefit from an immunosuppressive 
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regimen [14-19]. Both spontaneous remission and response 
to the immunosuppressive regimen is unpredictable [20]. 
 This study aims at developing a new approach in the 
process of discovery of proteins involved in the pathogenesis 
of iMN by focusing on a biological sample, the renal 
interstitial fluid (IF), obtained from biopsy specimens [21]. 
This pilot study confirms that the application of our 
approach is successful in identifying proteins specifically up-
regulated in the disease process and that the method is 
applicable to standard renal biopsy procedures without 
interfering with down-stream histological evaluation. The 
presence of a specific protein or peptide in the IF suggests its 
importance as a potential renal biomarker. Once novel 
biomarkers have been identified in IF, which differentiate 
among the various renal pathologies, their presence in more 
easily accessible samples such as urine and plasma can be 
tested. Indeed IF should be considered an invaluable 
biological fluid in the discovery phase of biomarkers, but in 
the process of validation for clinical use, it is pivotal to 
assess the availability of the biomarker in ‘usual’ samples: 
renal tissue, blood and/or urine. 
 In this study we identified the proteomic pattern of iMN 
with mass spectrometry analysis, comparing iMN IF samples 
with two control groups, normal kidney and patients with 
diagnoses other than iMN. The proteomic results were 
validated with immunofluorescence analysis on renal tissues 
and Western blot on serum, urines and human podocyte cell 
lines, providing the first evidence of the expression of LIM 
domain-related proteins in kidney and urines of iMN 
patients. 
MATERIALS AND METHODS 
Patients and Controls 
 Fifty-one patients were included in the study. We studied 
38 patients, from the Nephrology Dialysis and Renal 
Transplantation Division, three urologic patients from the 
Urologic Division (Table 1) and 10 healthy blood donors 
(HBD). After local Ethics Committee approval, informed 
consent was obtained from all participants. 
 Samples from 24 patients, who underwent kidney biopsy 
from January to June 2010, and 5 biopsies from one 
cadaveric donor kidney, were also used for proteomic 
analysis in IF. Six iMN, 6 IgA nephropathy (IgAN) and 3 
control kidneys (from cadaveric kidney and from two 
patients with a normal pathologic diagnosis, who had 
undergone kidney biopsy for minimal urinary abnormalities) 
were used for immunofluorescence analysis. Samples from 
10 iMN, 10 IgAN, 10 HBD and three urologic patients were 
tested by Western-blot analysis (Table 1). Kidney biopsy 
proven diagnoses were: idiopathic membranous nephropathy 
(iMN, n=10), IgA nephropathy (IgAN, n=10), mesangio- 
proliferative nephropathy with IgM depositions (IgMN, 
n=3), amyloidosis (AMIL, n=1), membranous proliferative 
glomerulonephritis (MPGN, n=3), intra and extra-capillary 
glomerulonephritis (IECG, n=1), minimal change disease 
(MCD, n=1), focal segmental glomerulosclerosis (FSGS, 
n=2), acute tubular necrosis (ATN, n=1), chronic interstitial 
nephritis (CIN, n=1), benign nephroangiosclerosis (BNA, n=1), 
diabetic nephropathy (DN, n=1), normal kidney (NK, n=3). 
Bladder pathology evaluations were: papillary urothelial 
carcinoma (PUCa, n=3), one with low grade and two with 
high grade. Healthy blood donor (HBD, n=10) did not 
undergo renal biopsy, but provided sera and urines. Cases of 
secondary MN were excluded from the present study, in 
particular patients with cancer, connective tissue diseases 
and active infectious diseases. All the samples of kidney, 
serum and urine were collected at the time of biopsy and 
prior to any immunosuppressive treatment (Table 1). 
Kidney Biopsy and Interstitial Fluid Extraction 
 Biopsy and IF extraction were performed as previously 
described [21]. In brief, renal biopsy specimens were 
centrifuged at 3000g for 7 min in a column with glass fiber 
filter (Roche), rehydrated with physiologic solution and 
underwent standard histological procedures. Compared to 
our previous protocol [21], in order to increase the recovery 
of proteins from the centrifugation filter, it was washed twice 
with 50ul of ultrapure water and centrifuged 15 minutes  
at 13,000g. Centrifuged fractions were pooled and stored  
at -80°C. 
Proteomic Analysis 
 Samples were thawed on ice, spun at 5000r.c.f. and the 
protein concentration, determined by a standard Bradford 
assay, were normalized with physiologic solution to a final 
concentration of 0.25ug/ul (1.2ug tot), treated with 5ul of 
ammonium bicarbonate (AMBIC) 100mM, reduced with 
Dithiothreitol (DTT 10mM, 1ul in AMBIC 100mM) at 56°C 
for 30min and alkylated with 4-vinyl pyridine (55mM, 1ul in 
AMBIC 100mM) at room temperature in the dark for 1h. 
The resulting protein mixtures were digested with TPCK-
modified sequencing grade trypsin (final ratio of enzyme  
to substrate 1:50 w/w) at 37°C overnight. Samples were  
then acidified with 1ul 5% formic acid (FA) solution and 
dried in a vacuum evaporator. Peptides were resuspended in 
30ul of 1% FA/acetonitrile 98:2 solution. Analyses were 
performed by ESI-Q-TOF Accurate-Mass G6520AA 
(Agilent Technologies), controlled by MassHunter (v. 
B.02.00) and interfaced by a CHIP-cube to an Agilent 1200 
nano-pump. Chromatographic separation was performed on 
a high capacity loading chip, with a 150mm, 300Å, C18 
column. Each biological replicate was run twice; analytical 
controls (a mix of baker’s yeast enolase and bovine serum 
albumin tryptic digests) were run daily to monitor 
chromatographic performances. Resulting mzData.xml raw 
data were searched against human SwissProt database with 
Mascot v. 2.3: search results were re-scored with Mascot 
Percolator [22] percolator score  50, at least two 
significantly scoring peptides/protein at 1% false discovery 
rate (detailed MIAPE-compliant methods are provided as 
Supplemental Methods). 
Label-free Relative Quantification 
 Exported re-scored Mascot search results were cross-
related to the corresponding MS1 profiles (mzXML format, 
converted from the vendor’s raw data by trapper, http:// 
sourceforge.net/projects/sashimi/files/trapper (MassHunter 
converter) by the quantitative software Ideal-Q [23], v. 1.024; 
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Table 1. Clinical characteristics of patients. 
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1 iMN F N 29 0,5 2,3 3,35 Y 12,1 125 75 98 168 Cauc N N N N N 
2 iMN M N 62 2,0 10,0 2,4 Y 13,9 192 97 74 175 Cauc N N N Y Y 
3 iMN M N 59 0,9 4,0 2,7 Y 15.7 130 80 98 182 Cauc N N N N N 
4 iMN F N 39 0,8 4,9 3,29 Y 13,6 118 76 66 162 Cauc N N N Y N 
5 iMN F N 85 1,0 11,5 2,3 Y 10,1 130 63 63 170 Cauc N N N Y N 
6 iMN M N 38 0,7 5,0 3,9 N 13,0 150 80 80 175 Cauc N N N N N 
7 iMN M N 43 1.15 4.6 1.6 N 11 135 80 107 170 Cauc N N N Y Y 
8 iMN M N 35 0.93 5 2.04 N 14.1 130 70 93 188 Cauc N N N N N 
9 iMN M N 34 0.81 1.3 4 Y 12.8 125 80 90 168 Cauc N N N N N 
10 iMN F N 47 0.6 10 2.5 N 11 130 75 83 164 Cauc N N N N N 
11 IgAN M N 41 3,2 9,1 2,9 Y 8,5 140 80 103 180 Cauc N Y Y Y N 
12 IgAN M N 36 1,0 0,1 4,3 Y 15,2 140 80 90 183 Cauc N N N Y N 
13 IgAN M N 41 0,5 0,0 3,9 Y 13,9 108 56 53 163 Cauc N N N Y N 
14 IgAN M N 42 0.6 0.4 4 Y 14.7 120 70 61 168 Cauc N N N N N 
15 IgAN F N 28 1 0.5 3 Y 12.7 110 78 64 160 Cauc N N N Y N 
16 IgAN M N 20 0.94 0.3 4.2 Y 13.9 123 65 62 182 Cauc N N N N N 
17 IgAN M N 65 1 0 4 Y 13.2 120 80 74 174 Cauc N N N N N 
18 IgAN M N 22 0.87 0.6 3.5 Y 15.4 130 70 70 172 Cauc N N N Y N 
19 IgAN M N 43 1.2 0.75 3 Y 17.3 120 70 92 170 Cauc N N N N N 
20 IgAN M N 33 1.4 0 4.1 Y 15.1 126 66 88 183 Cauc N N N N N 
21 IgMN M N 22 0,9 0,5 3,8 N 15,3 137 90 64 170 Cauc N N N Y N 
22 IgMN M N 56 0,7 6,1 3,26 Y 15,4 114 58 65 155 Cauc N N N N N 
23 IgMN F N 36 0,8 1,3 4 N 13,7 139 93 120 160 Cauc N N N N N 
24 AMIL F N 50 0,6 3,0 3,1 Y 12,5 131 86 68 165 Cauc N N N N N 
25 MPGN F N 77 1,9 0,6 NA N 9,6 140 80 59 152 Cauc N N N N N 
26 MPGN F N 74 1,0 1,9 2,6 Y 11,2 168 83 58 163 Cauc N N Y N N 
27 MPGN F N 42 0,8 1,4 2,4 Y 12,8 106 69 56 160 Cauc N N N N N 
28 IECG M N 85 4,5 6,3 2,4 Y 9,3 150 60 70 160 Cauc N N N N Y 
29 MCD M N 21 0,7 6,8 1,8 N 13,1 129 80 75 170 Cauc N N N Y N 
30 FSGS F N 25 0,7 5,4 2,5 N 14,1 110 70 56 165 Cauc N N N N N 
31 FSGS F Y 44 1,7 8,2 3,72 Y 11,2 142 89 63 173 Cauc N N N N N 
32 ATN M N 61 9,0 13,0 3,3 N 8,8 156 77 88 174 Cauc N N N N N 
33 CIN F N 48 0,7 0,2 4,02 Y 13,9 130 77 92 165 Cauc N N N Y N 
34 BNA F N 60 0,8 0,5 3,75 Y 11,7 149 87 72 160 Cauc N N N N N 
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Table 1. contd…. 
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35 DN M N 39 0,8 0,3 4,3 N 12,9 120 80 58 173 African N N N N Y 
36 NK F N 84 1.1 0 4.1 N 11.5 130 70 75 160 Cauc N N N N N 
37 NK F N 19 0.6 0 4.2 Y 12 117 63 75 175 Cauc N N N N N 
38 NK M N 44 1 0 4 Y 14.5 117 75 80 185 Cauc N N N N N 
39 *PUCa low grade M N 74 1.04 4 4.02 Y 12.2 140 95 90 170 Cauc N N N Y Y 
40 *PUCa high grade M N 89 1.88 3.2 3.8 Y 10.4 150 80 91 165 Cauc N N N Y Y 
41 *PUCa high grade M N 70 1.12 3 3.03 Y 12.6 140 90 110 180 Cauc N N N N Y 
42 HBD M N 37 1.1 0.02 4 N 14.4 130 80 89 185 Cauc N N N N N 
43 HBD M N 25 0.8 0 4.1 N 15 135 80 90 192 Cauc N N N N N 
44 HBD F N 23 0.9 0 3.8 N 11.8 90 60 58 170 African N N N N N 
45 HBD M N 20 0.8 0 4 N 13.8 110 75 78 180 Cauc N N N N N 
46 HBD F N 42 0.9 0 4.4 N 12.1 95 60 55 170 Cauc N N N N N 
47 HBD F N 40 1 0 4.3 N 11 100 60 52 158 Cauc N N N N N 
48 HBD F N 32 0.9 0.1 4 N 10.5 100 70 60 160 Cauc N N N N N 
49 HBD M N 27 1 0 4 N 14.8 90 60 65 170 Cauc N N N N N 
50 HBD M N 30 1.1 0 4 N 13.5 107 68 63 180 Cauc N N N N N 
51 HBD M N 31 1 0 4.1 N 15 100 80 78 175 Cauc N N N N N 
Legend. Biopsy pathologic diagnosis (*Bladder pathology evaluation), gender, patients age at diagnosis, serum creatinine (SCr), proteinuria (Pr), albuminemia (Alb), hemoglobin 
(Hb), systolic blood pressure (SBP), diastolic blood pressure (DBP), body weight, height, race (Caucasian=Cauc). Presence or absence (Yes=Y, No=N) of: kidney transplant (Tx 
Kidney), microhaematuria (Micro Hae), HbsAg, Anti-HIV, Anti-HCV, ACE/ARB, Diabetes. Biopsy pathologic diagnosis: idiopathic membranous nephropathy (iMN), IgA 
nephropathy (IgAN), mesangioproliferative nephropathy with IgM depositions (IgMN), amyloidosis (AMIL), membranous proliferative glomerulonephritis (MPGN), intra and extra-
capillary glomerulonephritis (IECG), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), acute tubular necrosis (ATN), chronic interstitial nephritis (CIN), 
benign nephroangiosclerosis (BNA), diabetic nephropathy (DN), normal kidney (NK), papillary urothelial carcinoma (PUCa). Healthy blood donor (HBD) did not underwent biopsy. 
 
pooled search iMGN unique hits were manually validated 
and quantified on the moverz/RT 2D map. Peptide raw XIC 
data were exported and elaborated through the DanteR tool 
(http://omic.pnl.gov/software/DanteR.php) [24]; briefly, peak 
areas were Log2 transformed, normalised (central tendency), 
then corresponding protein intensities were obtained from 
the peptides through an analysis of variance (p-value<0.05, 
Log20.5< protein ratio >Log22) and the inferred values were 
evaluated for statistical significance of differentially 
expressed proteins throughout the groups under study [24]. 
 The approach was validated on a group of 5 biopsy 
specimens from the same normal kidney; retention time 
reproducibility was evaluated by linear correlation of 
IDEAL-Q corrected elution times over the whole dataset 
(R2= 0.999 ), with an eXtracted Ion Current (XIC) CV of 
20%. False discovery rate was estimated through a 
concatenated decoy database search and was lower than 1% 
in all the search results. Percolated hits were visualised by 
protein family grouping and exported as XML or CSV with 
MudPIT scoring, reporting only unique peptide hits and the 
highest ranked proteins of each family. 
Antibodies 
 Primary: Mouse monoclonal anti-human LIM domain 
binding protein 3 antibody (LDB3); mouse monoclonal anti-
human PDZ and LIM domain protein 5 antibody (PDLI5); 
and mouse monoclonal anti-human Synaptopodin antibody 
were provided by Abnova (Abnova Corporation, Taipei, 
Taiwan). Protein A purified rabbit polyclonal anti-human 
Four and half LIM domains 1 antibody (FHL-1) and a mouse 
monoclonal IgG1 anti-human glyceraldehyde-3-phosphate 
dehydrogenase antibody (GAPDH) were provided by Santa 
Cruz (Santa Cruz Biotechnology Inc., Santa Cruz CA, USA). 
 Secondary: Goat anti-mouse IgG2a-Alexa 488 conjugate; 
goat anti-mouse IgG1-Alexa 568 conjugate; goat anti-mouse 
IgG2b-Alexa 568 conjugate; goat anti-mouse IgG2a-Alexa 
633 conjugate; goat anti-mouse IgG2b-Alexa 633 conjugate 
were all purchased from Invitrogen (Paisley, Scotland, UK). 
Donkey anti-rabbit Ig-FITC conjugate and sheep anti-mouse 
HRP conjugate were from GE Healthcare (Little Chalfont, 
Buckinghamshire, UK). Goat anti-rabbit IgG-Rhodamine 
conjugate and goat anti-rabbit IgG-HRP conjugated were 
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provided by Santa Cruz (Santa Cruz Biotechnology Inc., 
Santa Cruz CA, USA). DAPI Vectashield® Mounting 
Medium was provided by Vector Laboratories (Vector 
Laboratories, Inc., Burlingame, CA, USA). 
Immunofluorescence 
 Tissue samples for immunofluorescence staining were: 
six iMN, six IgAN and three control kidneys. Renal biopsy 
specimens were stored in a bio-bank at -80°C. Three-
micrometer frozen kidney samples were cut by a cryostat, 
fixed with Acetone, permeabilized with Triton 0.1%, coated 
with 3% BSA for 1h at 20°C. Primary antibody (1:20) was 
incubated for 1h at 37°C; the secondary antibody (1:1000) 
was later incubated for 1h at 20°C. Finally slides were closed 
with DAPI Vectashield® Mounting Medium. Biopsy 
samples were examined by immunofluorescence microscopy 
(Olympus BX41 Microscopy). Laser Confocal images 
(double-triple and co-localization staining) were obtained 
with Leica TCS SP2 (Leica Microsystems, Heidelberg, 
GmbH). Images of the glomerular area and labeled sections 
were traced digitally and intensity levels were analyzed with 
Leica Confocal Software v2.61 (Leica Microsystems 
Heidelberg, GmbH). Leica images were elaborated drawing 
a region of interest (ROI) around every single glomerulus in 
each slide; glomerular areas were normalized by background 
subtraction (using whole frame of image). Finally statistical 
data were analyzed using one way ANOVA. 
Western Blot of Serum, Urine and Podocyte Extracts 
 Serum separation [21], urine samples preparation [25] 
and protein concentration assay [25] were performed as 
previously described. Analysis of protein expression in 
serum and urine of 10 iMN, 10 IgAN, 10 HBD and three 
urologic patients was performed by Western blot assay [25] 
with GAPDH loading control. Western blotting was assessed 
also on human conditionally immortalized podocyte cell 
lines [26] under normal and oxidating conditions [8]. Urine 
protein extracts of patients and controls were normalized to 
0.8ug per loaded sample in order to refer to relative 
abundance instead of the whole proteinuria. In brief, each 
sample was loaded onto a 7.5% SDS-PAGE and then 
transferred to nitrocellulose membrane. After blocking for 1h 
at 20°C in a blocking solution, the membranes were incubated 
overnight at 4°C with the primary antibody (1:200) in 
blocking solution. Then the membranes were incubated with 
secondary antibody conjugated with horseradish peroxidase 
(1:2000) for 2h at 20°C. The signal was detected by 
NocexECL HRP Chemiluminescent Substrate Reagent Kit 
(Invitrogen, Paisley, Scotland, UK). Mini-PROTEAN Tetra 
Cell was used to perform 3 gel runs at the same time (one for 
iMN patients, one for IgAN patients and one for controls). 
Detailed information for serum and urine preparation, cell 
culture of podocyte and Western blot are described in 
Supplemental Methods. 
RESULTS 
Proteomic Analysis 
 Subjects (24 patients enrolled in the study and 5 biopsies 
from the cadaveric donor kidney as controls) were divided 
into three clinical classes for subsequent analyses: A) iMN 
patients (1-6, Table 1); B) normal kidney (38, Table 1) and 
C) patients with a pathological diagnosis other than iMN 
(11-13 and 21-35, Table 1). The renal biopsies from patients 
were processed to obtain the IF samples according to a 
procedure already published by our group [21]. Samples 
were digested and analyzed through liquid chromatography-
mass spectrometry to examine IF specific proteins. Two 
independent runs were performed for each sample. The 
analysis of variance of the A vs B + C groups showed a set 
of statistically significant differentially expressed candidate 
proteins (Supplementary Table 1). We focused our attention 
on a group of proteins integrating a LIM domain and 
functionally related, which were significantly over-expressed 
in this dataset (Table 2). The members of this class of 
proteins which we validated are FHL1 (Four and a half LIM 
domains protein 1), LDB3 (LIM Domain-Binding protein 3, 
also known as Cypher or ZASP) and PDLI5 (PDZ and LIM 
domain 5 protein). LIM-domain proteins have never been 
correlated to renal diseases until now. 
Immunofluorescence Analysis 
 We performed immunofluorescence analysis of tissue 
cryosections in order to confirm the results of proteomic 
analysis. We investigated the expression of FHL1, LDB3 
and PDLI5 in renal tissue of three controls, six IgAN and six 
iMN. We found that LDB3 and PDLI5 are strongly and 
specifically expressed in glomeruli of all iMN patients, while 
in IgAN patients both proteins are very weakly and focally 
expressed and completely absent in renal tissue from 
controls (Fig. 1). FHL1 is weakly and focally expressed in 
iMN patients, while it is not expressed in IgAN and controls. 
 Semi-quantitative analysis of FHL1, LDB3 and PDLI5 
expression was assessed through confocal morphometric 
evaluation of iMN and IgAN vs control patients. Glomerular 
expression of PDLI5 and LDB3 among iMN, IgAN patients 
Table 2. LIM Domain Proteins Over-expressed in Our Dataset 
UniProt AC PEP Description n.peptides Sequence Coverage (%) 
iMN vs. B+C Ratio 
(Log2) 
P value 
PDLI5_HUMAN 92 PDZ and LIM domain protein 5 2 6 2.1 2·10-3 
LDB3_HUMAN 68 LIM domain-binding protein3 2 10 7 1·10-6 
FHL1_HUMAN 52 Four and a half LIM domains protein 1 2 10 0.07 0.04 
Legend. iMN differentially expressed LIM -domain proteins, sorted for decreasing identification confidence (percolator post error probabilities, PEP). 
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and control subjects was significantly different, as judged by 
Kruskal Wallis analysis (Fig. 2). PDLI5: 2=25.890 with 2 
d.f. P <0.001; LDB3: 2=24.713 with 2 d.f. P <0.001. PDLI5 
is respectively more expressed in iMN than IgAN patients 
and both groups show higher expression than control 
patients. LDB3 is more highly expressed in iMN patients and 
IgAN patients than in control subjects, but there is no 
significant difference between iMN and IgAN patients for 
LDB3 expression.  
 The localization of the two proteins was defined by 
confocal microscopy: LDB3 and PDLI5 are expressed in 
podocyte cells, as confirmed in images at high magnification 
(Fig. 3: D, H). The podocyte localization has been confirmed 
by Synaptopodin costaining (Fig. 3). 
Western Blot Analysis of Serum, Urine and Podocyte 
Cell Lines 
 To evaluate the potential of these candidates as clinical 
biomarkers, we analyzed the expression of FHL1, LDB3 and 
PDLI5 in serum and urine of 10 iMN (1-10, Table 1), 10 
IgAN patients (11-20, Table 1) and 10 HBD (42-51, Table 1). 
LDB3 and PDLI5 are expressed in sera of analyzed patients 
 
Fig. (1). FHL1, LDB3 and PDLI5 expression by immunofluorescence analysis. LDB3 and PDLI5 are high expressed, while FHL1 is 
focally expressed in renal biopsies of iMN patients. Images A through C are stained for FHL1 (A from control, B from IgAN and C from 
iMN). D through F are stained for LDB3 (D control, E from IgAN and F from iMN). G through I stained for PDLI5 (G from control, H from 
IgAN and I from iMN). FHL1, LDB3 and PDLI5 staining are absent in renal biopsies from control tissue (A, D, G) and are very weakly 
expressed in IgAN (B, E, H). FHL1 is focally expressed in renal biopsies of iMN patients (C, L), LDB3 and PDLI5 and highly expressed in 
glomerular region of the same patients (F, I). 
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and controls (Fig. 4A). They are completely absent in the 
urine of control subjects, while they are present in that of the 
IgAN group and highly abundant in the urine of iMN 
patients (Fig. 4B). Western blot could not detect the presence 
of FHL1 in urine or serum (not shown). 
 Urine from three patients with urinary abnormality not 
related to glomerular disease were tested by Western blot 
analysis to confirm the hypothesis of a podocytic origin of 
PDLI5 and LDB3. All three patients were diagnosed for 
papillary urothelial carcinoma and their micro-haematuria 
and proteinuria did not have renal origin (Clinical details is 
provided in Table 1). Western blot did not show the 
existence of any specific bands of LDB3 and PDLI5 in these 
patients with urinary abnormalities related to urothelial 
carcinoma (Fig. 4C). 
 The podocyte expression of the proteins was further 
evaluated by Western blot on human podocyte cell lines 
extracts confirming the expression of LDB3 and PDLI5 in 
these cells (Fig. 4D), while the expression of FHL1 was 
absent. Electrophoresis shows the existence of a band of 
 
Fig. (2). Morphometric analysis. Morphometric semi-quantitative analysis of PDLI5 and LBD3 expression in glomerular region of iMN 
and IgAN patients vs controls. Results are expressed as percentage of the positive area for each antibody on total glomerular area. We 
analized all glomeruli on each slide. Results have high statistical significance for iMN and IgAN vs controls (*PDLI5: P <0.001; **LDB3: 
P<0.001). 
 
Fig. (3). LDB3 and PDLI5 expression in podocyte cells. LDB3, PDLI5 and Synaptopodin confocal laser scanning image of iMN patients. 
LDB3 (A) and Synaptopodin (B) do co-localize; merge image is reported (C). Both PDLI5 (E) and Synaptopodin (F) do colocalize and 
merge image is reported (G). High magnification merge images are reported: LDB3-Synaptopodin (D); PDLI5-Synaptopodin (H). 
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about 63.9 kDa for PDLI5 and about 77.1 kDa for LDB3. 
We did not find any difference in the expression of LDB3 in 
stressed podocyte cell lines, whereas PDLI5 was strongly 
overexpressed. This oxidative stress condition resembles the 
state of podocyte in membranous nephropathy (Fig. 4D). 
DISCUSSION 
 Based on our comparative proteomic analysis we 
obtained a list of proteins significantly expressed in iMN 
patients. In this study, we focused our attention on a group of 
them showing a common structural feature - the LIM domain 
- which is well represented among differentially expressed 
proteins of our dataset, namely FHL1, LDB3 and PDLI5. 
 Unlike other published studies [27], which required 
extensive tissue isolation and pre-fractionation procedures, in 
the present approach we were able to determine some iMN 
preferentially expressed proteins through a straightforward 
high-throughput proteomics approach. The key step of  
our strategy was a new method for obtaining a biological 
fluid from renal tissue, as previously described [21]. The 
procedure to obtain the fluid is simple and easily applicable 
to standard renal biopsy procedures. Although our approach 
has many advantages compared to other strategies, IF 
analysis may have some methodological weaknesses: in 
consideration of the experimental protocol there is the risk of 
IF contamination by non renal proteins and in particular 
from plasma proteins. This possibility has been explored in 
our previous article [21] in which we have effectively 
described the presence of plasma protein (transthyretin and 
haptoglobin). However, for the most part, IF overall protein 
composition is remarkably different from that of serum. 
Furthermore, serum proteins do not have a large impact on 
the final results; they are shared between disease and control 
samples and, therefore, were excluded from the candidate list 
after the statistical elaboration of data. 
 FHL1 is the most widely expressed member of the FHL 
family of proteins, consisting of four and a half highly 
conserved LIM domains. It is strongly expressed in skeletal 
muscle and to a lesser extent in heart; expression has never 
 
Fig. (4). LDB3 and PDLI5 Western blot of serum, urine and podocyte cell lines. Western Blot with LDB3 (77.1 KDa), PDLI5 (63.9 
KDa) and GAPDH loading control antibodies of serum, urine and podocyte cell lines. A) LDB3 and PDLI5  expression in sera. Lane 1-5 are 
IgAN patients; lane 6-10 are iMN; lane 11-15 are controls, HBD. LDB3 and PDLI5 are present in sera of analyzed patients and controls. B) 
LDB3 and PDLI5 in urines. Lane 1-5 are IgAN; lane 6-10 are iMN; lane 11-15 are controls, HBD. LDB3 and PDLI5 are completely absent 
in the urine of control subjects, while they are present in the urine of IgAN patients and they are highly abundant in the urine of iMN 
patients. C) Western Blot of urine of three urologic patients. LDB3 and PDLI5 are completely absent in the urine of this patients. D) Western 
Blot of podocyte cell lines extracts in normal (1) and oxidating conditions (2) showing bands of LDB3 and PDLI5. Note that PDLI5 is more 
expressed in cells under oxydating condition. 
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been reported in the kidney until now [28]. A multifunctional 
and integral role for FHL1 has been implicated in muscle 
development, structural maintenance and signaling. It 
contains four LIM domains and a novel single zinc finger 
domain in the N-terminal region [29-31]. 
 We could not confirm FHL1 as a specific iMN marker, as 
proteomic analysis preliminarily suggested: it is weakly 
expressed in glomeruli of iMN patients. Neither Western 
blot indicated a specific band in serum, urine or podocytic 
lines. 
 LDB3 is a member of the ALP (alpha-actinin-associated 
LIM protein) and enigma family and contains three LIM 
domains and one PDZ domain. LDB3 interacts via LIM 
domain with several phosphocreatine kinase (PKC) isoforms 
and via PDZ domain with alpha actinin [32, 33] (ACTN). It 
is expressed primarily in skeletal muscle and to a lesser 
extent in heart; it is also detectable in brain and placenta. 
LDB3 mRNA and protein are present in several cell lines 
and dog kidney [34], but no expression has been reported in 
human kidney so far. It may function as an adapter in 
cytoskeletal assembly, in the targeting and clustering of 
membrane proteins. It colocalizes with ACTN at sites of 
actin anchorage, such as the intercalated discs of cardiac 
muscle cells, since mutations in LDB3 can produce various 
cardiomyopathy. 
 PDLI5 is a member of the enigma family. It contains 
three LIM domains interacting with various PKC isoforms 
and one PDZ domain interacting with actin and alpha 
actinin. It is specifically expressed in heart and skeletal 
muscle [35], but no expression has been previously reported 
in human kidney. It is involved in heart development, 
regulation of cardiomyocyte expansion, heart hypertrophy, 
regulation of dendritic spine morphogenesis in neurons and 
postsynaptic growth. Its expression is commonly increased 
in the brain of patients with bipolar disorder, schizophrenia, 
and major depression [36, 37]. The functional LIM domain 
is involved in cytoskeleton organization by interaction with 
actin through the mediation of alpha-actinin. Due to 
interactions with the cytoskeleton, cytoplasmatic LIM-
domain proteins are also involved in many cellular 
physiological activities, such as cell shape modulation, cell 
motility and integrin-dependent adhesion and signaling [38]. 
 We found a strong expression of LDB3 and PDLI5 in 
glomeruli of all iMN patients, also confirmed by semi-
quantitative analysis in confocal microscopy. In the glomeruli 
of IgAN patients LDB3 is expressed in a similar fashion to 
patients affected by iMN, but PDLI5 is more highly 
expressed in iMN glomeruli than in IgAN glomeruli 
suggesting PDLI5 as the most specific marker for iMN. Both 
of the two proteins are weakly expressed or completely 
absent in controls. Western blot analysis on urine further 
confirms these results. These proteins are detectable in sera 
of analyzed patients and controls without significant 
differences between them. A noteworthy feature of these 
markers is their specific increase in the urine of the iMN 
patients suggesting their release from podocytes in the 
urinary space. We can exclude that the presence of these 
proteins in urine could derive from urinary cellular debris of 
podocytes because our preparative method includes a 
preliminary centrifugation step of the sample. 
 By using immunofluorescence technique we found a co-
localization of these two proteins with Synaptopodin 
confirming their podocyte expression, supported also by 
Western blot analysis of human podocyte cell lines in normal 
and stressed condition. Notably, PDLI5 expression levels are 
higher in peroxide stressed cells, a condition miming the 
oxidative stress on podocytes in iMN patients. 
 LDB3 and PDLI5 have never been described in the 
kidney compartment so far and our report is the first 
description of the presence of these components in the 
podocyte cytoskeleton. Our preliminary findings could be 
consistent with the hypothesis, recently reviewed by Mundel 
P and Reiser J [39], regarding the transition to a motile 
podocyte foot process state in response to external insults. 
The typical expression of these LIM domain-containing 
proteins by cells with a muscular phenotype could be related 
to the actin cytoskeleton plasticity [40, 38], also described in 
the proteinuric dysfunctional state of the podocyte. 
 In conclusion, the main contribution of this study is the 
identification of a protein family (LIM proteins) specifically 
expressed in podocyte of glomeruli from iMN patients; these 
biomarkers are easily detectable in organic fluids, thus 
encouraging the prospect of a minimally invasive diagnostic 
procedure. 
FUTURE DIRECTIONS 
 Our data suggest that LDB3 and PDLI5 are 
overexpressed in iMN. These preliminary data will require 
confirmation in a larger number of samples. For this reason, 
in the future, we are considering the need to repeat the 
morphometric semi-quantification of these proteins in the 
glomerulus of a large number of patients affected by iMN 
and other glomerulonephrites other than iMN. At the same 
time our data suggest that these proteins are present in the 
urine of the affected patients. For this reason the 
development of an assay that permits a quick and convenient 
measurement in the urine is one of our priorities. In 
particular, the development of an ELISA will improve our 
understanding of the role of these markers in a larger 
population of nephrotic patients. If the role of this family of 
LIM proteins is confirmed in iMN and nephrotic patients, the 
identification of molecules able to stabilize the cytoskeleton 
of the podocytes interacting with this system could lead to 
the development of novel agents with antiproteinuric 
activity. 
CONCLUSIONS 
 Interstitial fluid can be considered a valuable biological 
fluid in the discovery phase of biomarkers. We identified the 
proteomic pattern of idiopathic membranous nephropathy on 
IF with mass spectrometry analysis and these results were 
validated by immunofluorescence analysis on renal tissues 
and Western blot of serum, urines and podocyte cell cultures. 
We observed an increased expression of PDLI5 and LDB3 
providing the first evidence of the differential expression of 
these LIM domain-related proteins in kidney and urines of 
patients with idiopathic membranous nephropathy. In 
conclusion, our approach may be a method for identifying 
candidate biomarkers for patients suffering from membranous 
nephropathy and other glomerulonephrites. 
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ABBREVIATIONS 
ACTN = alpha actinin 
ALP = alpha-actinin-associated LIM protein 
AMBIC = ammonium bicarbonate 
AMIL = amyloidosis 
AR = aldose reductase 
ATN = acute tubular necrosis 
BNA = benign nephroangiosclerosis 
CIN = chronic interstitial nephritis 
DN = diabetic nephropathy 
DTT = Dithiothreitol 
ELISA = Enzyme-Linked ImmunoSorbent Assay 
ESI-QTOF = Elettrospray Quadrupole Time-of-Flight 
ESRF = end stage renal failure 
FA = formic acid 
FHL1 = Four and a half LIM domains protein 1 
FSGS = focal segmental glomerulosclerosis 
GAPDH = glyceraldehyde-3-phosphate 
dehydrogenase 
HBD = healthy blood donor 
IECG = intra and extra-capillary glomerulonephritis  
IF = interstitial fluid 
IgAN = IgA nephropathy 
IgMN = mesangioproliferative nephropathy with 
IgM depositions 
iMN = idiopathic membranous nephropathy 
LDB3 = LIM Domain-Binding protein 3 
MCD = minimal change disease 
MPGN = membranous proliferative glomerulonephritis 
NEP = neutral endopeptidase 
NK = normal kidney 
PDLI5 = PDZ and LIM domain 5 protein 
PKC = phosphocreatine kinase 
PLA2R = M-type phospholipase A2 receptor 
PUCa = papillary urothelial carcinoma 
SDS-PAGE = Sodium Dodecyl Sulphate - PolyAcrylamide 
Gel Electrophoresis 
SOD2 = manganese superoxide dismutase 
TPCK = Trypsin treated with L-1-tosylamido-2-
phenylethyl chloromethyl ketone 
XIC = eXtracted Ion Current 
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